Waratah Capital Advisors Ltd. Acquires Shares of 31,914 Illumina, Inc. (ILMN)

Waratah Capital Advisors Ltd. acquired a new stake in shares of Illumina, Inc. (NASDAQ:ILMN) in the third quarter, HoldingsChannel.com reports. The firm acquired 31,914 shares of the life sciences company’s stock, valued at approximately $11,714,000.

Several other institutional investors have also recently modified their holdings of ILMN. Millennium Management LLC grew its position in shares of Illumina by 219.8% during the second quarter. Millennium Management LLC now owns 548,957 shares of the life sciences company’s stock valued at $153,318,000 after purchasing an additional 377,283 shares in the last quarter. Jennison Associates LLC grew its position in Illumina by 4.5% in the second quarter. Jennison Associates LLC now owns 4,297,581 shares of the life sciences company’s stock worth $1,200,271,000 after acquiring an additional 185,745 shares in the last quarter. First Trust Advisors LP grew its position in Illumina by 42.0% in the third quarter. First Trust Advisors LP now owns 474,686 shares of the life sciences company’s stock worth $174,238,000 after acquiring an additional 140,364 shares in the last quarter. Fred Alger Management Inc. grew its position in Illumina by 21.4% in the second quarter. Fred Alger Management Inc. now owns 778,450 shares of the life sciences company’s stock worth $217,413,000 after acquiring an additional 137,302 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its position in Illumina by 75.8% in the second quarter. Assenagon Asset Management S.A. now owns 261,553 shares of the life sciences company’s stock worth $73,049,000 after acquiring an additional 112,757 shares in the last quarter. Hedge funds and other institutional investors own 89.88% of the company’s stock.

NASDAQ ILMN traded up $0.42 during trading on Friday, hitting $298.56. The stock had a trading volume of 57,527 shares, compared to its average volume of 914,652. The company has a debt-to-equity ratio of 0.22, a current ratio of 2.74 and a quick ratio of 2.44. The company has a market cap of $46.63 billion, a P/E ratio of 74.78, a PEG ratio of 2.63 and a beta of 0.97. Illumina, Inc. has a one year low of $202.20 and a one year high of $372.61.



Illumina (NASDAQ:ILMN) last announced its quarterly earnings data on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.26 by $0.26. The business had revenue of $853.00 million during the quarter, compared to the consensus estimate of $825.65 million. Illumina had a net margin of 20.88% and a return on equity of 26.64%. The firm’s quarterly revenue was up 19.5% compared to the same quarter last year. During the same quarter last year, the firm earned $1.11 earnings per share. As a group, equities research analysts expect that Illumina, Inc. will post 5.46 EPS for the current year.

In other Illumina news, insider Francis A. Desouza sold 2,100 shares of the firm’s stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $327.41, for a total value of $687,561.00. Following the completion of the sale, the insider now owns 77,935 shares of the company’s stock, valued at $25,516,698.35. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, EVP Marc Stapley sold 1,000 shares of the firm’s stock in a transaction dated Thursday, August 2nd. The stock was sold at an average price of $324.80, for a total transaction of $324,800.00. Following the completion of the sale, the executive vice president now directly owns 8,316 shares of the company’s stock, valued at approximately $2,701,036.80. The disclosure for this sale can be found here. In the last three months, insiders sold 51,983 shares of company stock valued at $17,546,488. 0.54% of the stock is owned by insiders.

Several research analysts recently commented on the company. UBS Group assumed coverage on Illumina in a research report on Tuesday, October 9th. They issued a “neutral” rating and a $340.00 price target for the company. Barclays lifted their price target on Illumina from $300.00 to $350.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 31st. Zacks Investment Research lowered Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday. Citigroup lifted their price target on Illumina from $330.00 to $345.00 and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Finally, Bank of America lifted their price target on Illumina from $345.00 to $370.00 and gave the stock a “buy” rating in a research report on Tuesday, July 31st. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $330.94.

Illumina Profile

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Featured Story: Marijuana Stocks

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN).

Institutional Ownership by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply